The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
13-Oct-16
$NA
Target:
Concordia International Corp
Advised the Special Committee of the Board of Directors of Concordia International, a diverse, international specialty pharmaceutical company focused on generic and legacy pharmaceutical products and orphan drugs, on its strategic review process
05-Oct-16
$775 million
Target:
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
05-Oct-16
$NA
Target:
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
Acquiror:
Accord Healthcare Ltd.
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
04-Oct-16
$223 million
Target:
US rights to Toprol-XL (AstraZeneca)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
08-Aug-16
$1.5 billion
Target:
Whistler Blackcomb Holdings Inc.
Acquiror:
Vail Resorts, Inc.
Advised Whistler Blackcomb Holdings Inc., a 75% owner and operator of the largest and most visited mountain resort in North America, on its sale to Vail Resorts, Inc.
20-Jun-16
$NA
Target:
US rights to 2 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Zydus Cadila
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 2 generic drug products to Zydus Cadila
15-Jun-16
$414 million
Target:
Aegerion Pharmaceuticals
Acquiror:
QLT Inc.
Advised QLT Inc. on its merger with Aegerion Pharmaceuticals and concurrent equity raise to create a rare disease-focused global biopharmaceutical organization
11-Jun-16
$350 million
Target:
US rights to 8 generic drug products from Teva Pharmaceutical Industries Ltd.
Acquiror:
Dr. Reddy’s Laboratories
Advised Teva Pharmaceutical Industries Ltd. on the divestment of the US rights to 8 generic drug products to Dr. Reddy’s Laboratories
18-Mar-16
$NA
Target:
Sewells Group
Acquiror:
MSX International
Advised WorldMark on the sale of Sewells Group to MSX International, a global provider of outsourced business solutions. Sewells, headquartered in Shanghai, is a leading provider of automotive dealership development services across Asia Pacific, Africa and the Middle East
20-Aug-15
$1.0 billion
Target:
COOEC Fluor Heavy Industries Co., Ltd.
Acquiror:
Fluor Corporation
Advised Fluor Corporation on its $489 million investment for a 49% interest in a joint venture with Offshore Oil Engineering Co., Ltd. (COOEC) to own, operate and manage the Zhuhai Fabrication Yard in China’s Guangdong province
27-Jul-15
$40.5 billion
Target:
Allergan Generics
Acquiror:
Teva Pharmaceutical Industries Ltd.
Advised Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, on the acquisition of Allergan plc’s Generics business
08-Jun-15
$45 million
Target:
Aralez Pharmaceuticals Inc.
Acquiror:
QLT Inc.
Advised QLT Inc. on its strategic equity investment in Aralez Pharmaceuticals Inc., a newly formed global specialty pharmaceutical company resulting from the business combination of POZEN Inc. and Tribute Pharmaceuticals Canada Inc., and the special distribution of the Aralez shares to QLT shareholders.
26-May-15
$2.2 billion
Target:
Nordstrom, Inc. (Credit Card Assets)
Acquiror:
The Toronto-Dominion Bank Group
Advised The Toronto-Dominion Bank Group on its acquisition of Nordstrom, Inc.’s credit card assets
03-Feb-15
$110 million
Target:
WEGU Holding GmbH
Acquiror:
Anhui Zhongding Sealing Parts
Advised the shareholders of WEGU Holding GmbH, a German provider of anti-vibration solutions and light-weight components for the automotive and truck industries, on the sale of the Company to Anhui Zhongding Sealing Parts, a Chinese listed company that makes and sells rubber sealing parts and other rubber products
22-Oct-14
$112 million
Target:
Nuplex Industries’ Specialties and Masterbatch businesses
Acquiror:
CHAMP Private Equity
Advised Nuplex Industries, a dual listed (ASX/NZX) global manufacturer, developer and distributor of resins and additives, on the sale of its specialty chemicals and masterbatch businesses to CHAMP Private Equity, a leading Australian private equity firm
13-May-14
$80 million
Target:
Publications International, Ltd. Children’s Division
Acquiror:
Jiangsu Phoenix Publishing and Media Corporation Limited
Advised Publications International, a leading consumer book publisher, on the sale of its Children’s Division to Jiangsu Phoenix Publishing and Media Corporation Limited
21-Dec-12
$75 million
Target:
Australian Portable Buildings
Acquiror:
Black Diamond Group Limited and WEQ Britco LP
Advised CHAMP Ventures on the sale of its portfolio company Australian Portable Buildings, a leading Australian manufacturer of customized modular buildings, to a consortium comprising Black Diamond Group and WEQ Britco
07-Dec-12
$43 million
Target:
Champion Flour Limited
Acquiror:
Nisshin Seifun Group Inc.
Advised Goodman Fielder, a leading Australian listed food company, on the sale of its New Zealand flour milling business, Champion Flour, to Nisshin Seifun Group Inc.
23-Oct-12
$5.7 billion
Target:
Target Corporation’s REDcard credit card assets
Acquiror:
The Toronto-Dominion Bank Group
Advised The Toronto-Dominion Bank Group on its acquisition of Target Corporation’s REDcard credit card assets
28-Jun-12
$275 million
Target:
Village Roadshow Entertainment Group
Advised Village Roadshow Entertainment Group on its $275 million mezzanine and equity capital raise from a group of investors
26-Mar-12
$513 million
Target:
ISTA Pharmaceuticals, Inc.
Acquiror:
Bausch + Lomb, Inc.
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its sale to Bausch + Lomb, Inc., a global ophthalmic products company
10-Nov-11
$318 million
Target:
MSF Sugar
Acquiror:
Mitr Phol Group
Advised MSF Sugar, Australia’s third largest producer and second largest exporter of sugar, on an acquisition proposal from Mitr Phol Sugar Corp. of Thailand at an offer value of ~31% premium to previous close
27-Jul-11
$850 million
Target:
The Synovate Group
Acquiror:
Ipsos S.A.
Advised Aegis Group plc on the sale of The Synovate Group, a leading global provider of custom market research, to Ipsos S.A.
21-Sep-10
$234 million
Target:
Taro Pharmaceutical Industries
Acquiror:
Sun Pharmaceutical Industries Ltd.
Advised Sun Pharmaceutical Industries Ltd., the largest Indian pharmaceutical company by market capitalization, on its acquisition of a majority interest in Israeli based Taro Pharmaceutical Industries, a multinational generics pharmaceutical company
10-Mar-10
$576 million
Target:
Camelot Group plc
Acquiror:
Ontario Teachers’ Pensions Plan
Advised the shareholders of Camelot – Cadbury, De La Rue, Fujitsu, Royal Mail and Thales – on the sale of their shareholdings in Camelot, the operator of the UK National Lottery, to Ontario Teachers’ Pensions Plan